Top

Published in:

01-06-2006 | Original Article

Methylenetetrahydrofolate reductase gene polymorphisms: genomic predictors of clinical response to fluoropyrimidine-based chemotherapy?

Authors: E. Marcuello, A. Altés, A. Menoyo, E. Del Rio, M. Baiget

Published in: Cancer Chemotherapy and Pharmacology | Issue 6/2006

Abstract

Fluorouracil (5-FU) is widely used in the treatment of colorectal cancer. Methylenetetrahydrofolate reductase (MTHFR) may play a central role in the action of 5-FU, an inhibitor of thymidylate synthase, by converting 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate. The aim of this study was to ascertain whether two polymorphisms in the MTHFR gene (677C>T and 1298 A>C) could be used as genomic predictors of clinical response to fluoropyrimidine-based chemotherapy (in combination with irinotecan or oxaliplatin). Ninety-four patients diagnosed with metastatic colorectal cancer and undergoing 5-FU-containing chemotherapy as a first line treatment were studied. The results suggest that the MTHFR genotype cannot be considered as an independent factor of outcome in colorectal cancer patients under 5-FU-based chemotherapy.

Cohen V, Panet-Raymond V, Sabbaghian N, Morin I, Batist G, Rozen R (2003) Methylenetetrahydrofolate reductase polymorphism in advanced colorectal cancer: a novel genomic predictor of clinical response to fluoropyrimidine-based chemotherapy. Clin Cancer Res 9:1611–1615PubMed

Danenberg PV (1977) Thymidylate synthetase: a target enzyme in cancer chemotherapy. Biochim Biophys Acta 473:73–92PubMed

Etienne MC, Llc K, Formento JL, Laurent-Puig P, Formento P, Cheradame S, Fischel JL, Milano G (2004) Thymidylate synthase and methylenetetradydrofolate reductase gene polymorphisms: relationships with 5-fluorouracil sensitivity. Br J Cancer 90:526–534CrossRefPubMed

Etienne MC, Formento JL, Chazal M, Francoual M, Magné N, Formento P, Bourgeon A, Seitz JF, Delpero JR, Letoublon C, Pezet D, Milano G, (2004) Pharmacogenetics 14:785–792CrossRefPubMed

Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, Boers GJH, den Heijer M, Kluijtmans LAJ, van den Heuvel LP, Rozen RA (1995) Candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nature Genet 10:111–113CrossRefPubMed

Goyette P, Pai A, Milos R, Frosst P, Tran P, Chen Z, Chan M, Rozen R (1998) Gene structure of human and mouse methylenetetrahydrofolate reductase (MTHFR). Mammalian Genome 9:652–656CrossRefPubMed

Gutierrez JI, Perez F, Calvo T, Tamparillas M, Gracia J (2003) Implicación de los polimorfismos C677T y A1298C del gen MTHFR en el desarrollo de los defectos del tubo neural en la población española. Med Clin (Barc) 120:441–445CrossRef

Jakobsen A, Nielsen JN, Gyldenkerne N, Lindeberg J (2005) Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphism in normal tissue as predictors of fluorouracil sensitivity. J Clin Oncol 23:1365–1369CrossRefPubMed

Kiffmeyer WR, Langer E, Davies S, Envall J, Robison L, Ross J (2004) Genetic polymorphisms in the Hmong population. Cancer 100:411–417CrossRefPubMed

10.

Longley DB, Harkin DP, Johnston PG, (2003) 5-Fluorouracil mechanisms of action and clinical strategies. Nat Rev Cancer 3:3330–338CrossRef

11.

Marcuello E, Altés A, Del Rio E, César A, Menoyo A, Baiget M (2004) Single nucleotide polymorphism in the 3’ tandem repeat sequences of thymidylate synthase gene predicts for response to fluorouracil-based chemotherapy in advanced colorectal cancer patients. Int J Cancer 112:733–737CrossRefPubMed

12.

Martinez-Frias ML, Bermejo E, Rodriguez-Pinilla E, Scala I, Andria G, Botto L, and ECEMC group (2004) Frecuencia de la mutacion 677C-T del gen de la metilentetrahidrofolato reductasa en una muestra de 652 recien nacidos de toda España. Med Clin (Barc) 122:361–364CrossRef

13.

Miller SA, Dykes DD, Polesky H (1989) A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16: 1215CrossRef

14.

Sekhon J, Pereira P, Sabbaghian N, Schievella AR, Rozen R (2002) Antisense inhibition of methylenetetrahydrofolate reductase reduces survival of methionine-dependent tumour lines. Br Jcancer 87:225–230CrossRef

15.

Sohn KJ, Croxford R, Yates Z, Lucock M, Kim YI (2004) Effect of the methylenetetrahydrofolate reductase C677T polymorphism on chemosensitivity of colon and breast cancer cells to 5-Fluorouracil and Methotrexate. J Natl Cancer Inst 96:134–144PubMedCrossRef

16.

Stankova J, Shang J, Rozen R (2005) Antisense inhibition of methylenetetrahydrofolate reductase reduces cancer cell survival In vitro and tumor growth in vivo. Clinical Cancer Research 11:2047–2052CrossRefPubMed

17.

Van der Put N, Gabreëls F, Stevens E, Smeitink J, Trijbels F, Eskes T, van den Heuvel L, Blom H (1998) A second common mutation in the methylenetetrahydrofolate reductase gene: An additional risk factor for neural-tube defects? Am J Hum Genet 62:1044–1051CrossRefPubMed

18.

Wilcken B, Bamforth F, Li Z, Zhu H, Ritvanen A, Redlund M, Stoll C, Alembik Y, Dott B, Czeizel AE, Gelman-Kohan Z, Scarano G, Bianca S, Ettore G, Tenconi R, Bellato S, Scala I, Mutchinick OM, Lopez MA, de Walle H, Hofstra R, Joutchenko L, Kavteladze L, Bermejo E, Martinez-Frias ML, Gallagher M, Erickson JD, Vollset SE, Mastroiacovo P, Andria G, Botto LD (2003) Geographical and ethnic variation of the 677C>T allele of MTHFR: findings from over 7000 newborns from 16 areas worldwide. J Med Genet 40:619–625CrossRefPubMed

19.

World Health Organization: Handbook for Reporting Results of Cancer Treatment. Publication n° 48. Geneva, Switzerland: World Health Organization; 1979)

Title: Methylenetetrahydrofolate reductase gene polymorphisms: genomic predictors of clinical response to fluoropyrimidine-based chemotherapy?
Authors: E. Marcuello
A. Altés
A. Menoyo
E. Del Rio
M. Baiget
Publication date: 01-06-2006
Publisher: Springer-Verlag
Published in: Cancer Chemotherapy and Pharmacology / Issue 6/2006
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-005-0089-1

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2006

Long intracellular retention of 4′-thio-arabinofuranosylcytosine 5′-triphosphate as a critical factor for the anti-solid tumor activity of 4′-thio-arabinofuranosylcytosine

Second-line chemotherapy in small cell lung cancer in a modified administration of topotecan combined with paclitaxel: a phase II study

The effect of cytostatic drug treatment on intestine-specific transcription factors Cdx2, GATA-4 and HNF-1α in mice

Phase I dose-finding study and a pharmacokinetic/pharmacodynamic analysis of the neutropenic response of intravenous diflomotecan in patients with advanced malignant tumours

In vivo antitumor efficacy and cardiotoxicity of novel anthracycline ID6105 (11-hydroxy-aclacinomycin X, Hyrubicin)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer